| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.76 [0.57, 1.02] | | < 1 | | 73% | 3 studies (3/-) | 96.6 % | some concern | not evaluable | moderate | crucial | - |
| progression or deaths (PFS) | 0.55 [0.45, 0.67] | | < 1 | | 27% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| objective responses (ORR) | 2.33 [1.78, 3.04] | | > 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.35 [0.12, 1.00] | | < 1 | | 79% | 3 studies (3/-) | 97.5 % | some concern | not evaluable | moderate | non important | - |
| AE (grade 3-4) | 0.56 [0.21, 1.52] | | < 1 | | 95% | 3 studies (3/-) | 87.2 % | some concern | not evaluable | moderate | non important | - |
| AE leading to death (grade 5) | 0.71 [0.34, 1.46] | | < 1 | | 45% | 3 studies (3/-) | 82.6 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 0.92 [0.54, 1.54] | | < 1 | | 52% | 3 studies (3/-) | 62.7 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 0.95 [0.59, 1.53] | | < 1 | | 5% | 2 studies (2/-) | 58.6 % | some concern | not evaluable | moderate | non important | - |
| STRAE (any grade) | 0.56 [0.35, 0.90] | | < 1 | | 0% | 1 study (1/-) | 99.2 % | NA | not evaluable | | non important | - |
| STRAE (grade 3-4) | 0.48 [0.28, 0.84] | | < 1 | | 0% | 1 study (1/-) | 99.5 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 0.24 [0.17, 0.34] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 0.34 [0.24, 0.49] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 0.63 [0.11, 3.82] | | < 1 | | 0% | 1 study (1/-) | 69.0 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (any grade) | 0.55 [0.31, 0.99] | | < 1 | | 0% | 1 study (1/-) | 97.8 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 1.28 [0.60, 2.75] | | < 1 | | 0% | 1 study (1/-) | 26.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 1.91 [0.06, 57.12] | | < 1 | | 0% | 1 study (1/-) | 35.6 % | NA | not evaluable | | non important | - |
| Alopecia TRAE (grade 3-4) | 0.95 [0.02, 48.21] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 0.01 [0.00, 0.19] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 0.12 [0.01, 0.94] | | < 1 | | 0% | 1 study (1/-) | 97.8 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 1.42 [0.11, 18.58] | | < 1 | | 0% | 2 studies (2/-) | 39.4 % | some concern | not evaluable | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 0.48 [0.02, 14.24] | | < 1 | | 0% | 1 study (1/-) | 66.3 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.24 [0.03, 2.13] | | < 1 | | 0% | 1 study (1/-) | 90.0 % | NA | not evaluable | | non important | - |
| Diabetes TRAE (grade 3-4) | 0.95 [0.02, 48.21] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.74 [0.16, 3.54] | | < 1 | | 0% | 3 studies (3/-) | 64.5 % | some concern | not evaluable | moderate | non important | - |
| Fatigue TRAE (grade 3-4) | 0.81 [0.27, 2.45] | | < 1 | | 0% | 1 study (1/-) | 64.2 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 1.92 [0.17, 21.22] | | < 1 | | 0% | 2 studies (2/-) | 29.9 % | some concern | not evaluable | moderate | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.77 [0.08, 7.39] | | < 1 | | 0% | 3 studies (3/-) | 59.0 % | some concern | not evaluable | moderate | non important | - |
| Hypophysitis TRAE (grade 3-4) | 0.95 [0.02, 48.21] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.48 [0.19, 11.68] | | < 1 | | 0% | 3 studies (3/-) | 35.7 % | some concern | not evaluable | moderate | non important | - |
| Increase AST TRAE (grade 3-4) | 1.75 [0.15, 19.96] | | < 1 | | 0% | 2 studies (2/-) | 32.7 % | some concern | not evaluable | moderate | non important | - |
| Increased ALT TRAE (grade 3-4) | 1.07 [0.08, 14.02] | | < 1 | | 0% | 2 studies (2/-) | 47.8 % | some concern | not evaluable | moderate | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.93 [0.06, 57.70] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.08 [0.00, 1.41] | | < 1 | | 0% | 1 study (1/-) | 95.6 % | NA | not evaluable | | non important | - |
| Nephritis TRAE (grade 3-4) | 0.96 [0.06, 15.36] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.02 [0.00, 0.18] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 1.93 [0.06, 57.70] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 2.05 [0.47, 8.85] | | < 1 | | 0% | 3 studies (3/-) | 17.0 % | some concern | not evaluable | moderate | non important | - |
| Pruritus TRAE (grade 3-4) | 0.68 [0.04, 10.98] | | < 1 | | 0% | 2 studies (2/-) | 60.4 % | some concern | not evaluable | moderate | non important | - |
| Rash TRAE (grade 3-4) | 1.08 [0.14, 8.52] | | < 1 | | 51% | 3 studies (3/-) | 47.1 % | some concern | not evaluable | moderate | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.03 [0.00, 0.42] | | < 1 | | 0% | 1 study (1/-) | 99.4 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.07 [0.00, 1.18] | | < 1 | | 0% | 1 study (1/-) | 96.6 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| hepatitis (Autoimmune) AE (grade 3-4) | 1.93 [0.06, 57.70] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Acute kidney injury AE (grade 3-4) | 0.24 [0.01, 5.34] | | < 1 | | 0% | 1 study (1/-) | 81.4 % | NA | not evaluable | | non important | - |
| Alopecia AE (grade 3-4) | 0.41 [0.04, 4.65] | | < 1 | | 0% | 2 studies (2/-) | 76.3 % | some concern | not evaluable | moderate | non important | - |
| Anaemia AE (grade 3-4) | 0.08 [0.02, 0.38] | | < 1 | | 73% | 2 studies (2/-) | 99.9 % | some concern | not evaluable | moderate | non important | - |
| Arthralgia AE (grade 3-4) | 0.48 [0.02, 14.38] | | < 1 | | 0% | 1 study (1/-) | 66.1 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 0.92 [0.40, 2.08] | | < 1 | | 0% | 2 studies (2/-) | 58.4 % | some concern | not evaluable | moderate | non important | - |
| Back pain AE (grade 3-4) | 0.36 [0.05, 2.37] | | < 1 | | 0% | 2 studies (2/-) | 85.5 % | some concern | not evaluable | moderate | non important | - |
| Blood creatinine increased AE (grade 3-4) | 0.48 [0.02, 14.38] | | < 1 | | 0% | 1 study (1/-) | 66.1 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 0.96 [0.10, 9.22] | | < 1 | | 0% | 2 studies (2/-) | 51.5 % | some concern | not evaluable | moderate | non important | - |
| Cough AE (grade 3-4) | 1.91 [0.06, 57.12] | | < 1 | | 0% | 1 study (1/-) | 35.6 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 1.34 [0.42, 4.27] | | < 1 | | 0% | 2 studies (2/-) | 31.0 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea AE (grade 3-4) | 0.27 [0.07, 1.00] | | < 1 | | 0% | 2 studies (2/-) | 97.5 % | some concern | not evaluable | moderate | non important | - |
| Dyspnoea AE (grade 3-4) | 1.65 [0.64, 4.24] | | < 1 | | 0% | 2 studies (2/-) | 14.8 % | some concern | not evaluable | moderate | non important | - |
| Fatigue AE (grade 3-4) | 1.04 [0.47, 2.31] | | < 1 | | 0% | 2 studies (2/-) | 46.4 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia AE (grade 3-4) | 0.06 [0.00, 1.03] | | < 1 | | 0% | 1 study (1/-) | 97.3 % | NA | not evaluable | | non important | - |
| Hypertension AE (grade 3-4) | 0.24 [0.01, 5.34] | | < 1 | | 0% | 1 study (1/-) | 81.4 % | NA | not evaluable | | non important | - |
| Increase AST AE (grade 3-4) | 4.87 [0.57, 41.91] | | < 1 | | 0% | 1 study (1/-) | 7.6 % | NA | not evaluable | | non important | - |
| Increased ALT AE (grade 3-4) | 5.82 [0.29, 116.64] | | < 1 | | 0% | 1 study (1/-) | 12.7 % | NA | not evaluable | | non important | - |
| Increased Lipase Level AE (grade 3-4) | 1.93 [0.06, 57.70] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Leucopenia AE (grade 3-4) | 0.10 [0.01, 0.83] | | < 1 | | 0% | 1 study (1/-) | 98.3 % | NA | not evaluable | | non important | - |
| myocarditis AE (grade 3-4) | 0.96 [0.02, 48.69] | | < 1 | | 0% | 1 study (1/-) | 50.7 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.14 [0.03, 0.80] | | < 1 | | 0% | 2 studies (2/-) | 98.6 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia AE (grade 3-4) | 0.06 [0.02, 0.15] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| Pancytopenia (AE grade 3-4) | 0.48 [0.02, 14.38] | | < 1 | | 0% | 1 study (1/-) | 66.1 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy AE (grade 3-4) | 0.96 [0.06, 15.46] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Peripheral sensory neuropathy AE (grade 3-4) | 0.48 [0.02, 14.38] | | < 1 | | 0% | 1 study (1/-) | 66.1 % | NA | not evaluable | | non important | - |
| Pneumonia AE (grade 3-4) | 0.77 [0.20, 2.88] | | < 1 | | 0% | 1 study (1/-) | 65.2 % | NA | not evaluable | | non important | - |
| Pneumonitis AE (grade 3-4) | 1.93 [0.06, 57.70] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 0.95 [0.02, 48.21] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 5.76 [0.29, 115.45] | | < 1 | | 0% | 1 study (1/-) | 12.9 % | NA | not evaluable | | non important | - |
| Rash AE (grade 3-4) | 3.72 [0.61, 22.69] | | < 1 | | 0% | 2 studies (2/-) | 7.8 % | some concern | not evaluable | moderate | non important | - |
| Rash maculopapular AE (grade 3-4) | 1.93 [0.06, 57.70] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
| Stomatitis AE (grade 3-4) | 0.48 [0.02, 14.38] | | < 1 | | 0% | 1 study (1/-) | 66.1 % | NA | not evaluable | | non important | - |
| Thrombocytopenia AE (grade 3-4) | 0.04 [0.01, 0.18] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| Vomiting AE (grade 3-4) | 0.43 [0.14, 1.35] | | < 1 | | 0% | 2 studies (2/-) | 92.6 % | some concern | not evaluable | moderate | non important | - |
| Weight decreased AE (grade 3-4) | 2.54 [0.39, 16.78] | | < 1 | | 0% | 2 studies (2/-) | 16.7 % | some concern | not evaluable | moderate | non important | - |
